This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

PR examination and screening or diagnosis of prostate cancer

Authoring team

Digital rectal examination (DRE) should be offered to men with lower urinary tract symptoms or symptoms suggestive of metastatic disease (1).

DRE can be used to detect:

  • the prostate for signs of prostate cancer - a hard gland, sometimes with palpable nodules
  • benign enlargement - smooth, firm, enlarged gland (1)

Symmetric enlargement is a common finding in aging men (2). A gland which feels normal in DRE does not exclude a tumour (1)

The effectiveness of DRE in detecting prostate cancer is not well established

  • estimated sensitivity is fairly poor (53% to 59%) while the specificity is better (83% to 94%)
  • many early prostate cancers will not be detected by DRE (1)
  • studies have shown that in patients who had a biopsy done based on DRE findings, 72% to 82% of will not have prostate cancer
  • in addition, around quarter of patients who had prostate cancers detected with biopsy after abnormal DRE findings, prostate cancer was found in a different area than to the DRE findings (2).

DRE is not recommended as a screening test in asymptomatic men (1)

A single study with symptomatic men showed (3):

  • sensitivity and specificity for DRE as a predictor of prostate cancer in symptomatic patients was 28.6 and 90.7%, respectively. The positive and negative predictive values were 42.3 and 84.2%, respectively.

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.